tailieunhanh - báo cáo khoa học: "Updates in Gastrointestinal Oncology – insights from the annual meeting of the American Society of Clinical Oncology"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Updates in Gastrointestinal Oncology – insights from the annual meeting of the American Society of Clinical Oncology | Journal of Hematology Oncology BioMed Central Open Access Review Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology Milind Javle1 and Chung-Tsen Hsueh 2 Address Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston TX 77030 USA and 2Division of Medical Oncology and Hematology Loma Linda University Loma Linda CA 92354 USA Email Milind Javle - mjavle@ Chung-Tsen Hsueh - chsueh@ Corresponding author Published 23 February 2009 Received 17 January 2009 Journal of Hematology Oncology 2009 2 9 doi 1756-8722-2-9 Accepted 23 February 2009 This article is available from http content 2 l 9 2009 Javle and Hsueh licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract We have reviewed the pivotal presentations rcelated to colorectal cancer CRC and other gastrointestinal malignancies from 2008 annual meeting of the American Society of Clinical Oncology ASCO . We have discussed the scientific findings and the impact on practice guidelines and ongoing clinical trials. The report on KRAS status in patients with metastatic CRC receiving epidermal growth factor receptor EGFR targeted antibody treatment has led to a change in National Comprehensive Cancer Network guideline that recommends only patients with wild-type KRAS tumor should receive this treatment. The results of double biologics bevacizumab and anti-EGFR antibody plus chemotherapy as first-line treatment in patients with metastatic CRC has shown a worse outcome than bevacizumab-based regimen. Microsatellite Instability has again been confirmed to be an important predictor in patients with stage II colon cancer